Effectiveness of recombinant hepatitis B vaccine

ABSTRACT

The study was carried out to see the efficacy of recombinant hepatitis B vaccine in two high risk groups viz; chronic renal failure patients on maintenance haemodialysis [n = 20] and medical staff [n = 25]. The pre-vaccination status of these individuals was assessed by HBsAg, Anti-HBs and LFTs. Only those subjects were included in this study who were negative for HBsAg and Anti-HBs. The patients were given 2cc while the staff 1cc dose of the vaccine intramuscularly at the schedule of 0,1 and 6 months. Quantitative estimation of antibody titre [seroconversion] was noted by ELISA method 15 days after the last dose. This became positive in 84% of the medical staff members and 65% of the patients in a concentration of >/= 10 IU/L. No significant side effects were noted in any of the subject